Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.57 |
| ▸ | PARG | Q86W56 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10739672 | 0.88 | ALDH1A1 (0.70) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL19661983 | 0.87 | KCNH2 (0.66) | ALDH1A1CYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL754592 | 0.85 | MEN1 (0.56) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL16732898 | 0.84 | KDM4E (0.62) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL20893375 | 0.84 | MAPT (0.62) | ALDH1A1CYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL788918 | 0.84 | KCNH2 (0.67) | MEN1KMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30136795 | 0.84 | MAPT (0.62) | ALDH1A1CYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL9378819 | 0.84 | KDM4E (0.69) | ALDH1A1HPGDSMN1; SMN2HIF1APARG | |
| SCHEMBL1473247 | 0.83 | KDM4E (0.69) | MEN1KMT2AALDH1A1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6979902 | 0.83 | KDM4E (0.60) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275958-A1 | GPCR REGULATOR AND USE THEREOF | Beijing Changping Laboratory (CN) | 2025-09-04 | — | — | US | disclosed |
| EP-4512803-A1 | GPCR REGULATOR AND USE THEREOF | Beijing Changping Laboratory (CN) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023202578-A1 | GPCR REGULATOR AND USE THEREOF | 北京昌平实验室 | 2023-10-26 | — | — | WO | disclosed |
| CN-116903562-A | GPCR modulators and uses thereof | 北京昌平实验室 | 2023-10-20 | — | — | CN | disclosed |
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-7915300-B2 | Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-20080234260-A1 | Cysteine Protease inhibitors | MEDIVIR AB (SE) | 2008-09-25 | — | — | US | disclosed |
| WO-2005066180-A9 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-09-25 | — | — | WO | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006715-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| EP-1701960-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005066180-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234260-A1 | Cysteine Protease inhibitors | CTSS, CTSZ, CTSK | MEN1 2218/4885KMT2A 1492/4885ALDH1A1 4169/4885 |
| US-20110112089-A1 | Cysteine Protease Inhibitors | CTSS, CTSZ, CTSK | MEN1 2181/4885KMT2A 1689/4885ALDH1A1 4297/4885 |
| US-20250275958-A1 | GPCR REGULATOR AND USE THEREOF | ARRB1, GPR3, GPR4 | MEN1 3421/4885KMT2A 2867/4885ALDH1A1 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.